Address SGLT2 Inhibitor Use in the Hospital
September 2022
You’ll need to ensure appropriate use of SGLT2 inhibitors (empagliflozin, etc)...as more hospitals add these meds to formulary.
It’s partly because guidelines for heart failure with reduced ejection fraction (HFrEF) now recommend “quad therapy”...adding an SGLT2 inhibitor (SGLT2i) to triple therapy, regardless of diabetes.
Plus guidelines suggest an SGLT2i for patients with heart failure with mildly reduced EF (HFmrEF) or preserved EF (HFpEF).Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote